title: [Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].
authors.affiliation: Service de pharmacovigilance, hôpital Central, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54035 Nancy cedex, France.
authors.forename: P
authors.initials: P
authors.lastname: Trechot
authors.forename: J-L
authors.initials: JL
authors.lastname: Schmutz
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000368:Aged; D000409:Alanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors*; D001381:Azepines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D004359:Drug Therapy, Combination; D057239:Early Termination of Clinical Trials; D005260:Female; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects / Q000378:metabolism; D008559:Memantine / Q000627:therapeutic use; D008954:Models, Biological; D018697:Nootropic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D048448:Phenylcarbamates / Q000627:therapeutic use; D011565:Psoriasis / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy; D051880:Receptors, Notch / Q000502:physiology; D000068836:Rivastigmine; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000305:Adrenal Cortex Hormones; D001381:Azepines; C484278:N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide; D018697:Nootropic Agents; D048448:Phenylcarbamates; D051880:Receptors, Notch; D053829:Amyloid Precursor Protein Secretases; D000409:Alanine; D000068836:Rivastigmine; D008559:Memantine